The FDA's recent update on LDT regulations has raised questions about their implications for the biotech industry and the necessary adjustments for companies. We consulted Software QA Manager Ashwini Manjunath for insights into what these changes entail, particularly for small firms, and to share Strand’s experience with adapting laboratories to various global regulations.

Read our solution snapshot for more details.